MEDP

In the past six months, Medpace's stock has been influenced by several key events. The company reported strong financial results for Q4 2025 (reported February 2026), with robust revenue growth of $708.5 million (up 32.0% year-over-year) and GAAP net income of $135.1 million, alongside significant share repurchases and optimistic 2026 guidance. Q1 2026 results (reported April 2026) showed revenue of $706.6 million, a 26.5% year-over-year increase, and GAAP net income of $123.9 million, with full-year 2026 guidance reiterated. For Q2 2026 (reported July 22, 2026), Medpace exceeded analyst expectations with diluted EPS of $4.25 and quarterly revenue of $707.33 million (up 17.2% year-over-year), driven by a 28.2% surge in net new business awards to $795.7 million, resulting in a 1.13x net book-to-bill ratio and a backlog exceeding $3.01 billion, which led management to raise full-year 2026 guidance and positively impacted investor sentiment. Medpace also allocated $294.7 million for the repurchase of 705,616 shares during the first half of 2026. However, CEO August J. Troendle engaged in significant insider selling, including 10,880 shares for approximately $6.75 million on September 21, 2026, contributing to over $341 million in insider sales over the past 12 months, which some analysts view as a caution signal. Additionally, the stock has faced an overhang from a newly disclosed shareholder investigation by Bronstein, Gewirtz & Grossman into potential claims on behalf of purchasers.